Innovating Works

dreaMS

Financiado
Digital biomarkers and treatment personalisation in multiple sclerosis
Multiple Sclerosis (MS) diagnosis is based on neurologists’ assessment using a combination of tools: MRI, physical and cognitive assessments and patient reported symptoms. It is well accepted that current tools do not paint a pro... Multiple Sclerosis (MS) diagnosis is based on neurologists’ assessment using a combination of tools: MRI, physical and cognitive assessments and patient reported symptoms. It is well accepted that current tools do not paint a proper picture of the patient illness leading to the need of additional insights into patient symptoms. dreaMS aims to be the 1st digital solution for patient with MS providing digital biomarkers to help with diagnosis, prognosis and treatment choice. The solution supports both patients and providers, allowing for more precise treatment strategies and continuous monitoring, resulting in improved patient outcomes and well-being. Our technology is easy scalable to other diseases treatment (like Alzheimer, schizophrenia, or any neurological illness) The global MS treatment market was valued at $16.13 Billion in 2016, and is expected to reach $27.38 Billion by 2025, driven by the continued uptake of premium products and an increase in treatment rates because of the availability of novel alternatives based on digital solutions. dreaMS will enter to the European digital biomarkers market, which is facing major changes that will reshape the competitive environment for solution vendors and service providers during the coming years. Our key users will be neurologists and MS patients that will use the dreaMS technology. Additionally, because dreaMS benefits among value chain (both users and buyers) we will guarantee a global impact. Phase 1 will center on preparing a feasibility study. This will include the following activities: full identification and characterization of our target market, design of the internationalization and business development strategy, definition of technological needs and product validation, identification and clearance of legal issues and definition of our IPR strategy, and finally, design of the finance strategy and a business plan. We plan to use SMEI-1 to identify interested buyers to take part in demonstrations in SMEI-2. ver más
30/09/2019
Healios LLC
71K€
Duración del proyecto: 4 meses Fecha Inicio: 2019-05-06
Fecha Fin: 2019-09-30

Línea de financiación: concedida

El organismo H2020 notifico la concesión del proyecto el día 2019-09-30
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
EIC-SMEInst-2018-2020: SME instrument
Cerrada hace 6 años
Presupuesto El presupuesto total del proyecto asciende a 71K€
Líder del proyecto
HEALIOS LLC No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5